KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study

Human Immunology

Volumn 76, Issue 9, 2015, Pages 636-643

  Park, Silvia ^a   Kim, Kihyun ^a   Jang, Jun Ho ^a   Kim, Seok Jin ^a   Kim, Won Seog ^a   Kang, Eun Suk ^a   Jung, Chul Won ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Alloreactivity; KIR; NK cell

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; HLA ANTIGEN; LIGAND;

ACUTE LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ARTICLE; BLOOD; CANCER SURVIVAL; CANCER THERAPY; DISEASE FREE SURVIVAL; DONOR; FEMALE; HAPLOTYPE; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; RECIPIENT; SOUTH KOREA; TREATMENT OUTCOME; ADOLESCENT; ADVERSE EFFECTS; ALLOTRANSPLANTATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LEUKEMIA; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; LEUKEMIA; LIGANDS; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, KIR; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84944441018     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2015.09.009     Document Type: Article

References (39)

1. Lim Z., Brand R., Martino R., van Biezen A., Finke J., Bacigalupo A., et al. Allogeneic hematopoietic stem-cell transplantation for patients 50years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J. Clin. Oncol. 2010, 28:405-411.
2. Gupta V., Tallman M.S., Weisdorf D.J. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 2011, 117:2307-2318.
3. Barrett A.J., Battiwalla M. Relapse after allogeneic stem cell transplantation. Expert Rev. Hematol. 2010, 3:429-441.
4. Mohty M., Kuentz M., Michallet M., Bourhis J.H., Milpied N., Sutton L., et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 2002, 100:3128-3134.
5. Hiemenz J.W. Management of infections complicating allogeneic hematopoietic stem cell transplantation. Semin. Hematol. 2009, 46:289-312.
6. Bleakley M., Riddell S.R. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat. Rev. Cancer 2004, 4:371-380.
7. Kolb H.J., Schmid C., Barrett A.J., Schendel D.J. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004, 103:767-776.
8. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112:4371-4383.
9. Miller J.S. Therapeutic applications: natural killer cells in the clinic. Hematol. Am. Soc. Hematol. Educ. Program 2013, 2013:247-253.
10. Lanier L.L., Le A.M., Civin C.I., Loken M.R., Phillips J.H. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J. Immunol. 1986, 136:4480-4486.
11. Spits H., Di Santo J.P. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat. Immunol. 2011, 12:21-27.
12. Biron C.A., Byron K.S., Sullivan J.L. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 1989, 320:1731-1735.
13. Leung W. Use of NK cell activity in cure by transplant. Br. J. Haematol. 2011, 155:14-29.
14. Peruzzi M., Wagtmann N., Long E.O. A p70 killer cell inhibitory receptor specific for several HLA-B allotypes discriminates among peptides bound to HLA-B*2705. J. Exp. Med. 1996, 184:1585-1590.
15. Hansasuta P., Dong T., Thananchai H., Weekes M., Willberg C., Aldemir H., et al. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur. J. Immunol. 2004, 34:1673-1679.
16. Thananchai H., Gillespie G., Martin M.P., Bashirova A., Yawata N., Yawata M., et al. Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J. Immunol. 2007, 178:33-37.
17. Colonna M., Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995, 268:405-408.
18. Wagtmann N., Biassoni R., Cantoni C., Verdiani S., Malnati M.S., Vitale M., et al. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. Immunity 1995, 2:439-449.
19. Uhrberg M., Valiante N.M., Shum B.P., Shilling H.G., Lienert-Weidenbach K., Corliss B., et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997, 7:753-763.
20. Caligiuri M.A. Human natural killer cells. Blood 2008, 112:461-469.
21. D'Andrea A., Chang C., Franz-Bacon K., McClanahan T., Phillips J.H., Lanier L.L. Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotypes. J. Immunol. 1995, 155:2306-2310.
22. Valiante N.M., Parham P. Natural killer cells, HLA class I molecules, and marrow transplantation. Biol. Blood Marrow Transplant. 1997, 3:229-235.
23. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
24. Bishara A., De Santis D., Witt C.C., Brautbar C., Christiansen F.T., Or R., et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 2004, 63:204-211.
25. Huang X.J., Zhao X.Y., Liu D.H., Liu K.Y., Xu L.P. Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. Leukemia 2007, 21:848-851.
26. Vago L., Forno B., Sormani M.P., Crocchiolo R., Zino E., Di Terlizzi S., et al. Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood 2008, 112:3488-3499.
27. Symons H.J., Leffell M.S., Rossiter N.D., Zahurak M., Jones R.J., Fuchs E.J. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol. Blood Marrow Transplant. 2010, 16:533-542.
28. Leung W., Iyengar R., Turner V., Lang P., Bader P., Conn P., et al. Determinants of antileukemia effects of allogeneic NK cells. J. Immunol. 2004, 172:644-650.
29. Gagne K., Brizard G., Gueglio B., Milpied N., Herry P., Bonneville F., et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum. Immunol. 2002, 63:271-280.
30. McQueen K.L., Dorighi K.M., Guethlein L.A., Wong R., Sanjanwala B., Parham P. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum. Immunol. 2007, 68:309-323.
31. Ruggeri L., Mancusi A., Capanni M., Urbani E., Carotti A., Aloisi T., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110:433-440.
32. Beksac M., Dalva K. Role of killer immunoglobulin-like receptor and ligand matching in donor selection. Bone Marrow Res. 2012, 2012:271695.
33. Cooley S., Trachtenberg E., Bergemann T.L., Saeteurn K., Klein J., Le C.T., et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009, 113:726-732.
34. Stringaris K., Adams S., Uribe M., Eniafe R., Wu C.O., Savani B.N., et al. Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol. Blood Marrow Transplant. 2010, 16:1257-1264.
35. Chen C., Busson M., Rocha V., Appert M.L., Lepage V., Dulphy N., et al. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant. 2006, 38:437-444.
36. Middleton D., Gonzelez F. The extensive polymorphism of KIR genes. Immunology 2010, 129:8-19.
37. Singh K.M., Phung Y.T., Kohla M.S., Lan B.Y., Chan S., Suen D.L., et al. KIR genotypic diversity can track ancestries in heterogeneous populations: a potential confounder for disease association studies. Immunogenetics 2012, 64:97-109.
38. Whang D.H., Park H., Yoon J.A., Park M.H. Haplotype analysis of killer cell immunoglobulin-like receptor genes in 77 Korean families. Hum. Immunol. 2005, 66:146-154.
39. Zhou Q., Wang J., He Z., Li X., Mao S., Huang S., et al. KIR diversity in three ethnic minority populations in China. J. Transl. Med. 2015, 13:221.